Ellagic acid inhibits high glucose‑induced injury in rat mesangial cells via the PI3K/Akt/FOXO3a signaling pathway

Lin, Wei; Liu, Guojian; Kang, Xiaowen; Guo, Ping; Shang, Yu; Du, Ruomei; Wang, Xiyue; Chen, Liting; Yue, Rui; Kong, Fanzhi; Zhu, Qing

doi:10.3892/etm.2021.10449

Cited by 14 publications

(7 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it delays the development of chronic diseases. Research on the mechanism of glucose metabolism has shown that EA reduces serum glucose levels in rats by activating 5′AMP-activated protein kinase [ 54 ]. It also mitigates glucose-induced damage to pancreatic mesangial cells by activating the PI3K/Akt/FOXO3 signaling pathway, restoring pancreatic cell function, and reducing serum glucose concentration [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

Effects of Ellagic Acid on Glucose and Lipid Metabolism: A Systematic Review and Meta‐Analysis

Wang,

Zhou,

Zhang

2024

Journal of Nutrition and Metabolism

View full text Add to dashboard Cite

Background. Abnormal glucose and lipid metabolism (GALM) serve as both a cause and an inducer for the development of the disease. Improvement and treatment of GALM are an important stage to prevent the occurrence and development of the disease. However, current clinical treatment for GALM is limited. Ellagic acid (EA), a common polyphenol present in foods, has been shown to improve abnormalities in GALM observed in patients suffering from metabolic diseases. Objective. This study used a meta‐analysis method to systematically assess the effects of EA on GALM. Method. As of November 8, 2023, a comprehensive search was conducted across 5 databases, namely, PubMed, Embase, Web of Science, Cochrane Library, and Google Scholar to identify randomized controlled trials (RCTs) in which EA served as the primary intervention for diseases related to GALM. The risk of bias within the included studies was assessed according to the Cochrane Handbook. All statistical analyzes were performed using RevMan 5.4 software. Results. In this study, a total of 482 articles were retrieved, resulting in the inclusion of 10 RCTs in the meta‐analysis. The results showed that EA could reduce fasting blood glucose (FBG) (p = 0.008), increase insulin secretion (p = 0.01), improve insulin resistance index (HOMA‐IR) (p = 0.003), decrease triglyceride (TG) (p = 0.004), and reduce cholesterol (Chol) (p = 0.04) and low‐density lipoprotein (LDL‐c) (p = 0.0004). EA had no significant effect on waist circumference (WC), body weight (BW), body mass index (BMI), 2 hours after prandial blood glucose (2 h‐PG), total cholesterol (TC), and high‐density lipoprotein (HDL‐c). Conclusions. The effect of improvement in glucose and lipids of EA was closely related to the dose and the intervention time. EA can improve GALM caused by diseases. To corroborate the findings of this study and improve the reliability of the results, EA is imperative to refine the research methodology and increase the sample size in future investigations.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Ellagic Acid on Glucose and Lipid Metabolism: A Systematic Review and Meta‐Analysis

Wang,

Zhou,

Zhang

2024

Journal of Nutrition and Metabolism

View full text Add to dashboard Cite

show abstract

“…It prevented the PI3K/Akt signalling pathway, which was activated by high glucose levels in mesangial cells, and then controlled the nuclear transcription activities of FOXO3 and NF-kB, which in turn prevented cell division, oxidative stress, the release of inflammatory factors, and the production of ECM. The current study offered an experimental theoretical foundation for the process by which ellagic acid lessened the harm that elevated glucose levels induced to mesangial cells [39].…”

Section: Ellagic Acidmentioning

confidence: 91%

Insights into the Therapeutic uses of Plant Derive Phytocompounds on Diabetic Nephropathy

Mitra,

Jana,

Roy

2024

CDR

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is one of the primary consequences of diabetes mellitus, affecting many people worldwide and is the main cause of death under the age of sixty. Reactive oxygen species (ROS) production rises during hyperglycemia and is crucial to the development of diabetic complications. Advanced glycation end products (AGEs) are produced excessively in a diabetic state and are accumulated in the kidney, where they change renal architecture and impair renal function. Another important targeted pathway for the formation of DN includes nuclear factor kappa-B (NF-kB), Nuclear factor E2–related factor 2 (Nrf2), NLR family pyrin domain containing 3 (NLRP3), protein kinase B/mammalian target of rapamycin (Akt/mTOR), and autophagy. About 40% of individuals with diabetes eventually acquire diabetic kidney disease and end-stage renal disease that needs hemodialysis, peritoneal dialysis, or kidney transplantation to survive. The current state of acceptable therapy for this kidney ailment is limited. The studies revealed that some naturally occurring bioactive substances might shield the kidney by controlling oxidative stress, renal fibrosis, inflammation, and autophagy. In order to provide new potential therapeutic lead bioactive compounds for contemporary drug discovery and clinical management of DN, this review was designed to examine the various mechanistic pathways by which conventional plants derive phytocompounds that are effective for the control and treatment of DN.

show abstract

“…It also activated different antioxidant enzymes, such as HO-1, NQO1, GST, and GSH [ 216 , 217 ]. The dysfunction of mesangial cells in diabetic nephropathy might be related to the PI3K/Akt signaling pathway activation inhibited by ellagic acid [ 218 ]. Ellagic acid treatment also triggered SIRT1 overexpression in renal tissues, which imparted renal tolerance to oxidative stress [ 214 ].…”

Section: Antioxidants and Kidney Diseasesmentioning

confidence: 99%

The Effect of Polyphenols on Kidney Disease: Targeting Mitochondria

Ashkar

Bhullar

2022

Nutrients

View full text Add to dashboard Cite

Mitochondrial function, including oxidative phosphorylation (OXPHOS), mitochondrial biogenesis, and mitochondria dynamics, are essential for the maintenance of renal health. Through modulation of mitochondrial function, the kidneys are able to sustain or recover acute kidney injury (AKI), chronic kidney disease (CKD), nephrotoxicity, nephropathy, and ischemia perfusion. Therapeutic improvement in mitochondrial function in the kidneys is related to the regulation of adenosine triphosphate (ATP) production, free radicals scavenging, decline in apoptosis, and inflammation. Dietary antioxidants, notably polyphenols present in fruits, vegetables, and plants, have attracted attention as effective dietary and pharmacological interventions. Considerable evidence shows that polyphenols protect against mitochondrial damage in different experimental models of kidney disease. Mechanistically, polyphenols regulate the mitochondrial redox status, apoptosis, and multiple intercellular signaling pathways. Therefore, this review attempts to focus on the role of polyphenols in the prevention or treatment of kidney disease and explore the molecular mechanisms associated with their pharmacological activity.

show abstract

Ellagic acid inhibits high glucose‑induced injury in rat mesangial cells via the PI3K/Akt/FOXO3a signaling pathway

Cited by 14 publications

References 56 publications

Effects of Ellagic Acid on Glucose and Lipid Metabolism: A Systematic Review and Meta‐Analysis

Effects of Ellagic Acid on Glucose and Lipid Metabolism: A Systematic Review and Meta‐Analysis

Insights into the Therapeutic uses of Plant Derive Phytocompounds on Diabetic Nephropathy

The Effect of Polyphenols on Kidney Disease: Targeting Mitochondria

Contact Info

Product

Resources

About